Ion channel modulation provides an opportunity for therapeutic intervention to treat neurological disorders. However, unintended interference also presents risk in disruption of normal CNS function and potential therapeutic liabilities.

This webinar explores neurological ion channel therapeutic and liability targets, featuring four subtypes of NMDA receptors. We also discuss the rationale and options for assessment of therapeutic compounds on panels of CNS ion channels for evaluating their risk for CNS liabilities.


  • Luke Armstrong, PhD, Associate Director, Cell Molecular Biology, Charles River
  • Nikolai Fedorov, PhD, Principal Scientist, Charles River